×
For media inquiries, contact pr@bluenotetx.com.
Blue Note Therapeutics Raises $26.25 Million in Series A Financing
March 2021
Company announces closing of Series A financing to scale the organization and support lead candidate, BNT001.
Read more →
Blue Note Therapeutics Partnering with Patient Advocacy Groups to Provide Digital Cancer-Related Mental Health Care During Pandemic
January 2021
Blue Note Therapeutics' 2020 year-end wrap-up.
Blue Note Therapeutics Enters Licensing Agreement with Massachusetts General Hospital for Digital Therapeutic for Acute Myeloid Leukemia Patients
October 2020
Blue Note prepares to advance development of online mental health treatment for those with AML.
Blue Note Therapeutics Enters Agreement to Create a Prescription Digital Therapeutic Medical Device for Cancer Patients
September 2020
Memorial Sloan Kettering Cancer Center (MSK) and Blue Note Therapeutics, Inc. have agreed to collaborate on creating a prescription digital therapeutic medical device from a psychological intervention created specifically for cancer patients with advanced cancer.
Blue Note Therapeutics Receives Breakthrough Device Designation from FDA for Prescription Digital Therapeutic to Treat Cancer-Related Anxiety and Depression
June 2020
Blue Note Therapeutics, Inc. announced that the U.S. FDA has granted Breakthrough Device Designation to BNT001, the company’s lead prescription digital therapeutic (PDT) candidate.
Blue Note Therapeutics Enters Licensing Agreement with the University of Miami
May 2020
The agreement allows Blue Note to develop and commercialize a prescription digital therapeutic for stress management in cancer patients.
Do you have comments or inquiries about our products in development, partnering opportunities or career opportunities? Write to us here.
Note: if you are a study participant, please contact your study coordinator.
